Literature DB >> 11045998

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.

F W van Ginkel1, R J Jackson, Y Yuki, J R McGhee.   

Abstract

We tested the notion that the mucosal adjuvant cholera toxin (CT) could target, in addition to nasal-associated lymphoreticular tissues, the olfactory nerves/epithelium (ON/E) and olfactory bulbs (OBs) when given intranasally. Radiolabeled CT ((125)I-CT) or CT-B subunit ((125)I-CT-B), when given intranasally to mice, entered the ON/E and OB and persisted for 6 days; however, neither molecule was present in nasal-associated lymphoreticular tissues beyond 24 h. This uptake into olfactory regions was monosialoganglioside (GM1) dependent. Intranasal vaccination with (125)I-tetanus toxoid together with unlabeled CT as adjuvant resulted in uptake into the ON/E but not the OB, whereas (125)I-tetanus toxoid alone did not penetrate into the CNS. We conclude that GM1-binding molecules like CT target the ON/E and are retrograde transported to the OB and may promote uptake of vaccine proteins into olfactory neurons. This raises concerns about the role of GM1-binding molecules that target neuronal tissues in mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045998     DOI: 10.4049/jimmunol.165.9.4778

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  92 in total

1.  Polymer hydrogels: Chaperoning vaccines.

Authors:  Herman F Staats; Kam W Leong
Journal:  Nat Mater       Date:  2010-07       Impact factor: 43.841

2.  Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.

Authors:  Chenlu Liu; Tomomi Hashizume; Tomoko Kurita-Ochiai; Kohtaro Fujihashi; Masafumi Yamamoto
Journal:  Mol Oral Microbiol       Date:  2010-06       Impact factor: 3.563

3.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

4.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

Review 5.  Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.

Authors:  Alan Smith; Michael Perelman; Michael Hinchcliffe
Journal:  Hum Vaccin Immunother       Date:  2013-12-17       Impact factor: 3.452

6.  TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.

Authors:  Brooke E Hjelm; Jacquelyn Kilbourne; Melissa M Herbst-Kralovetz
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

7.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 8.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

9.  A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity.

Authors:  Shee Eun Lee; Soo Young Kim; Byung Chul Jeong; Young Ran Kim; Soo Jang Bae; Ouk Seon Ahn; Je-Jung Lee; Ho-Chun Song; Jung Mogg Kim; Hyon E Choy; Sun Sik Chung; Mi-Na Kweon; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 10.  Innate sensors of influenza virus: clues to developing better intranasal vaccines.

Authors:  Takeshi Ichinohe; Akiko Iwasaki; Hideki Hasegawa
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.